Traders Sell Pfizer, Inc. (PFE) on Strength Following Insider Selling
Investors sold shares of Pfizer, Inc. (NYSE:PFE) on strength during trading hours on Wednesday after an insider sold shares in the company. $56.94 million flowed into the stock on the tick-up and $120.07 million flowed out of the stock on the tick-down, for a money net flow of $63.13 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.09 for the day and closed at $33.24Specifically, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the sale, the insider now owns 151,474 shares in the company, valued at $5,074,379. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The disclosure for this sale can be found here. Insiders sold 120,014 shares of company stock worth $4,062,493 in the last quarter. Company insiders own 0.06% of the company’s stock.
Several research firms recently commented on PFE. Berenberg Bank restated a “hold” rating and set a $36.00 price target (down previously from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a research report on Monday, August 14th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 5th. Jefferies Group LLC restated a “hold” rating and set a $35.00 price target on shares of Pfizer in a research report on Friday, August 18th. Finally, UBS AG restated a “buy” rating and set a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. Two investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $37.61.
The company has a 50-day moving average price of $33.26 and a 200 day moving average price of $33.41. The stock has a market cap of $197.69 billion, a P/E ratio of 24.32 and a beta of 1.00.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The company had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the previous year, the business posted $0.64 EPS. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts predict that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be paid a dividend of $0.32 per share. The ex-dividend date of this dividend is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.85%. Pfizer’s dividend payout ratio (DPR) is presently 94.12%.
Institutional investors have recently added to or reduced their stakes in the stock. Farmers National Bank boosted its position in Pfizer by 3.2% in the second quarter. Farmers National Bank now owns 107,106 shares of the biopharmaceutical company’s stock valued at $3,598,000 after buying an additional 3,352 shares during the period. RNC Capital Management LLC boosted its position in Pfizer by 3.7% in the second quarter. RNC Capital Management LLC now owns 1,080,976 shares of the biopharmaceutical company’s stock valued at $36,310,000 after buying an additional 38,619 shares during the period. Sentry Investment Management LLC boosted its position in Pfizer by 1.0% in the second quarter. Sentry Investment Management LLC now owns 478,557 shares of the biopharmaceutical company’s stock valued at $16,075,000 after buying an additional 4,775 shares during the period. Atlantic Trust LLC boosted its position in Pfizer by 19.8% in the second quarter. Atlantic Trust LLC now owns 27,400 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 4,530 shares during the period. Finally, WFG Advisors LP boosted its position in Pfizer by 14.5% in the second quarter. WFG Advisors LP now owns 55,528 shares of the biopharmaceutical company’s stock valued at $1,865,000 after buying an additional 7,024 shares during the period. 69.94% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This report was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.watchlistnews.com/traders-sell-pfizer-inc-pfe-on-strength-following-insider-selling/1519088.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.